A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs Authors: Sang Gyun Kim, Tae-Oh Kim, Sung Woo Jung, Byung-Hoon Min, Jung-Hwan Oh, Hyun-Soo Kim, Gil Ho Lee, Ji Hyun Song, In Kyung Sung, Young Sin Cho, Suck Chei Choi, Yun Jeong Lim, Byung-Wook Kim, Cheol Min Shin, Cheal Wung Huh, Ji Won Kim, Kyung-Oh Kim, Yu Kyung Cho, Oh Young Lee, Jeong Seop Moon, Hyun Woo Lee, Hwoon-Yong Jung, Woon Geon Shin, Jae-Gyu Kim, Ju Yup Lee, Su Jung Han, Sang-Wook Kim, Joon Hyun Cho, Hyun Lim, Tae Ho Kim, Moo In Park, Gwang Ho Baik, Ra Ri Cha, Sang Kil Lee, Jae J Kim Published: 2026 ABSTRACT AbstractBackground/AimsLong-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcers. Tegoprazan, a novel potassium-competitive acid blocker, provides rapid and potent inhibition of acid production. This study evaluated whether tegoprazan 25 mg is non-inferior to lansoprazole 15 mg in preventing NSAID-induced peptic ulcer.MethodsIn this double-blind, randomized, active-controlled, multicenter phase III trial, patients requiring NSAIDs for up to 24 weeks were randomized (11) to the tegoprazan or the lansoprazole group. The primary endpoint was the incidence of peptic ulcer at week 24 in the per-protocol population. Secondary endpoints were NSAID-induced gastrointestinal symptom-free rates. Safety outcomes included adverse drug reactions (ADRs) and serious adverse events (SAEs).ResultsA total of 392 patients were randomized, and 269 patients were analyzed in the per-protocol set. Tegoprazan was non-inferior to lansoprazole for the prevention of gastroduodenal ulcers (p=0.0004). The heartburn-free rate at week 12 was higher in the tegoprazan group (p=0.0421), while other symptom-free rates did not differ significantly. In terms of safety, ADR and SAE rates were comparable and not significantly different.ConclusionsTegoprazan was non-inferior to lansoprazole in preventing NSAID-induced peptic ulcers with excellent tolerance. Tegoprazan represents a clinically effective alternative gastroprotective therapy (ClinicalTrials.gov identifier NCT04840550).Keywords: Tegoprazan; Lansoprazole; Anti-Inflammatory agents, non-steroidal; Peptic ulcer; Potassium-competitive acid blocker INTRODUCTION Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used drugs for fever, pain, and inflammation, particularly in older patients.1 Their chronic use is associated with increased risks of gastroduodenal ulcers and life-threatening gastrointestinal complications.1 Preventive strategies remain essential to ensure medication adherence and patient safety. Although proton pump inhibitors (PPIs) have been a standard therapy for the prevention of NSAID-induced peptic ulcer, notable limitations have remained in terms of delayed onset, nocturnal acid breakthrough, drug interactions and poor adherence to dosing schedules. Potassium-competitive acid blockers (P-CABs) have mostly overcome unmet needs of PPIs by rapid and effective acid suppression without requiring proton pump activation. In real-world practice, patients requiring long-term NSAID therapy are often elderly and exposed to multiple concomitant medications, raising concerns regarding interindividual variability in acid suppression with PPIs. In this context, acid inhibition that is rapid, potent, and less influenced by metabolic polymorphism may provide clinically meaningful advantages. P-CABs have shown potent pharmacodynamic effects and a beneficial effect in preventing ulcer recurrence in NSAID or aspirin users.2-4 In a systematic review and meta-analysis, P-CABs demonstrated non-inferiority to lansoprazole in the management of peptic ulcer.5 In an animal study, a P-CAB showed protective effects against NSAID-induced small intestinal injury by preservation of intestinal barrier integrity, modulation of inflammatory responses and restoration of gut microbiota composition.6 Tegoprazan, a novel P-CAB, has shown a high efficacy in treating acid-related gastrointestinal disorders including erosive esophagitis, non-erosive reflux disease, gastroduodenal ulcer, and Helicobacter pylori eradication.7-11 Also, tegoprazan showed a protective effect against NSAID-induced small bowel injury by enhancement of the expression levels of tight junction proteins and the suppression of inflammation and apoptosis in an in vitro study.12 The aim of the study was to evaluate the non-inferiority of tegoprazan to lansoprazole for the prevention of peptic ulcers in long-term NSAID users and the safety and tolerability of tegoprazan. MATERIALS AND METHODS 1. Study population and design This study was conducted as a double-blind, randomized, active-controlled, multicenter phase III trial to evaluate the non-inferiority of tegoprazan to lansoprazole to prevent peptic ulcers in long-term NSAID users. Patients were randomized to the tegoprazan group or the lansoprazole group for 24 weeks, in 7:3 stratified block (non-selective NSAIDs: cyclooxygenase-2 [COX-2] selective inhibitors). Endoscopic evaluation was performed at baseline and 24 weeks. At baseline, 4, 12, and 24 weeks, NSAID-induced gastrointestinal symptoms, including heartburn, acid regurgitation, and epigastric pain or discomfort, were evaluated. Clinical laboratory test results, vital signs, compliance, and adverse events (AEs) were evaluated at baseline and 24 weeks. This study was performed in accordance with the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines. The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (SNUH IRB number: 2106-003-1223). Written informed consent was obtained from all subjects prior to any study-related procedure. This study was registered at ClinicalTrials.gov (identification number: NCT04840550; study title: “Study to Evaluate the Safety and Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs”). 2. Study subjects and protocol Subjects were enrolled when they met the following criteria: (1) age over 20 years with a history of peptic ulcer (endoscopically confirmed gastroduodenal ulcer scar or medical record of endoscopically confirmed gastroduodenal ulcer); (2) age over 60 years; (3) patients requiring continuous NSAIDs for over 24 weeks for management of musculoskeletal disorders. Subjects were excluded if they had: (1) endoscopically confirmed ulcers of active or healing stage, bleeding, perforation, esophageal stricture, ulcer stricture, pyloric stricture, esophageal or gastric varix, Barrett esophagus, gastrointestinal malignancy; (2) alarm symptoms suggestive of gastrointestinal malignancy; (3) history of upper gastrointestinal surgery which may affect acid secretion; (4) history of Zollinger-Ellison syndrome; (5) history of malignancy within 5 years prior to screening; (6) abnormal laboratory tests on screening; (7) co-administration of corticosteroids, antiplatelets except low-dose aspirin or anticoagulants. After randomization, patients received tegoprazan 25 mg and a placebo of lansoprazole, or lansoprazole 15 mg and placebo of tegoprazan once daily, 30 minutes before breakfast. The treatment was completed after 24 weeks. Antacid was provided as rescue medication once daily, up to two pouches per week. During the study period, the following concomitant medications were prohibited: (1) PPI; (2) P-CAB; (3) histamine-2 receptor antagonist; (4) bismuth; (5) anticholinergics; (6) cholinergics; (7) gastrin inhibitor; (8) mucosal protectants; (9) prokinetics; (10) antacids; (11) antivirals; (12) antiplatelets except low-dose aspirin; (13) anticoagulants; (14) corticosteroids. 3. Outcome evaluation The primary endpoint was the proportion of patients with peptic ulcer during 24 weeks of treatment. According to the Sakita-Miwa classification, peptic ulcer was defined as active, healing or newly developed scar stage. The secondary endpoint was the proportion of NSAID-induced gastrointestinal symptom-free patients at weeks 4, 12, and 24. NSAID-induced gastrointestinal symptoms were defined as heartburn, acid regurgitation, or epigastric pain or discomfort. Safety was evaluated in terms of treatment-emergent AEs (TEAEs), clinical laboratory tests, vital signs, 12-lead electrocardiogram, and physical examination. TEAEs included AEs, adverse drug reactions, and serious AEs (SAEs). 4. Statistical analysis The sample size was calculated based on the primary endpoint. By assuming the rate of peptic ulcer development as 5.5% in each group with an 8.3% non-inferiority margin and 85% power to detect non-inferiority of tegoprazan to lansoprazole with a one-sided significance level of 2.5%, 136 subjects were required for randomization to each group. After allowing for 30% dropouts, 195 subjects were finally randomized to each group.4 Efficacy was assessed primarily using the per-protocol set (PPS) and secondarily using the full analysis set (FAS). Safety was assessed using the safety analysis set. FAS included all patients randomized to the groups who received at least one dose of study medication. The PPS included all patients who had an evaluable primary endpoint, excluding those with major protocol violations, randomization errors, use of prohibited drugs, and low compliance. The safety analysis set included all patients who received at least one dose of the study medication and had at least one safety assessment. For efficacy evaluation, 95% confidence intervals (CI) for the difference in proportions between the two groups were calculated. When data were sparse, defined as more than 20% of cells having an expected frequency of less than 5, exact unconditional confidence limits (based on the Farrington-Manning method) were used; otherwise, the Wald CIs were applied. For the primary endpoint, the non-inferiority of tegoprazan versus lansoprazole was declared if the upper bound of the two-sided 95% CI for the difference between the two arms was lower than the non-inferiority margin of 8.3%. For the secondary endpoint, non-inferiority was declared if the lower bound of the two-sided 95% CI for the difference between the two arms was greater than the non-inferiority margin of –8.3%. To further evaluate the difference between the two groups, a superiority test was conducted using the chi-square test or Fisher exact test. All statistical analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA) in accordance with the analysis plan. Continuous variables were expressed as number of participants, mean, standard deviation, median, minimum and maximum values. Categorical variables were presented as frequencies and percentages. All statistical analyses were performed at a significance level of two-sided 5% unless otherwise specified in the protocol. RESULTS 1. Study subjects A total of 582 patients were screened, and eligible patients were randomized to either the tegoprazan group (n=195) or the lansoprazole group (n=197). After randomization, patients discontinued the study due to withdrawal of informed consent (n=46), violation of inclusion/exclusion criteria (n=11), changes in NSAID regimen (n=3), investigator discretion (n=8) and investigator's judgment of AE (n=6), loss to follow-up (n=3). Ultimately, 315 patients completed the study (Fig. 1). Baseline demographics and clinical characteristics were comparable between the two groups (Table 1). Study disposition. AE, adverse event; NSAID, nonsteroidal anti-inflammatory drug. Table 1Demographic and Baseline Characteristics (FAS)Tegoprazan 25 mg (n=153)Lansoprazole 15 mg (n=163)Total (n=316)p-valueSex0.9180†Male60 (39.22)63 (38.65)123 (38.92)Female93 (60.78)100 (61.35)193 (61.08)Age group0.0237†20–5931 (20.26)18 (11.04)49 (15.51)≥60122 (79.74)145 (88.96)267 (84.49)Smoking0.4292†Yes14 (9.15)11 (6.75)25 (7.91)No139 (90.85)152 (93.25)291 (92.09)Drinking0.0995†Yes31 (20.26)46 (28.22)77 (24.37)No122 (79.74)117 (71.78)239 (75.63)History of gastroduodenal ulcer0.2138†Yes40 (26.14)33 (20.25)73 (23.10)No113 (73.86)130 (79.75)243 (76.90)Concomitant use of low-dose aspirin0.6892†Yes7 (4.58)6 (3.68)13 (4.11)No146 (95.42)157 (96.32)303 (95.89)No. of risk factors*0.6002‡1137 (89.54)142 (87.12)279 (88.29)216 (10.46)21 (12.88)37 (11.71)3000Stratification by NSAID type0.7995†COX-2 selective inhibitors44 (28.76)49 (30.06)93 (29.43)Non-selective NSAIDs109 (71.24)114 (69.94)223 (70.57)Aceclofenac40 (26.14)37 (22.70)77 (24.37)Others69 (45.10)77 (47.24)146 (46.20)Data are presented as number (%).FAS, full analysis set; NSAID, nonsteroidal anti-inflammatory drug; COX-2, cyclooxygenase-2.*Age ≥60 years, history of gastroduodenal ulcer, concomitant use of low-dose aspirin; †Chi-square test; ‡Fisher exact test. Demographic and Baseline Characteristics (FAS) Data are presented as number (%). FAS, full analysis set; NSAID, nonsteroidal anti-inflammatory drug; COX-2, cyclooxygenase-2. *Age ≥60 years, history of gastroduodenal ulcer, concomitant use of low-dose aspirin; †Chi-square test; ‡Fisher exact test. 2. Efficacy Regarding the primary endpoint, the proportion of patients in the PPS population with endoscopically confirmed peptic ulcers within 24 weeks was not inferior for the tegoprazan 25 mg group (1.49%, 2/134) compared with the lansoprazole 15 mg group (2.22%, 3/135) (Table 2, Fig. 2). As the upper bound of the two-sided 95% CI for the difference between the two arms was <8.3%, the non-inferiority of tegoprazan to lansoprazole was verified. Table 2Proportion of Subjects with Gastric and/or Duodenal Ulcers at Week 24 (Non-Inferiority Test)Tegoprazan 25 mgLansoprazole 15 mgPPSNo.134135Proportion (%) of subjects with gastric and/or duodenal ulcers at week 242 (1.49)3 (2.22)Difference from lansoprazole 15 mg–0.7395% CI for difference–5.16 to 3.37*p-value0.0004†FASNo.153163Proportion (%) of subjects with gastric and/or duodenal ulcers at week 243 (1.96)3 (1.84)Difference from lansoprazole 15 mg0.1295% CI for difference–3.59 to 4.09*p-value0.0005†Note: confidence interval (CI), non-inferiority margin 8.3%.PPS, per-protocol set; FAS, full analysis set.*Exact unconditional CI; †Non-inferiority test (Farrington-Manning method). Proportion of Subjects with Gastric and/or Duodenal Ulcers at Week 24 (Non-Inferiority Test) Note: confidence interval (CI), non-inferiority margin 8.3%. PPS, per-protocol set; FAS, full analysis set. *Exact unconditional CI; †Non-inferiority test (Farrington-Manning method). Primary endpoint. Proportion of patients in the per-protocol set (A) and the full analysis set (B) with endoscopically confirmed peptic ulcers at week 24. *Non-inferiority test (Farrington-Manning method). In FAS analysis, the proportion of patients with endoscopically documented peptic ulcers within 24 weeks was also not inferior for the tegoprazan 25 mg group (1.96%, 3/153) compared with the lansoprazole 15 mg group (1.84%, 3/163), also supporting the non-inferiority of tegoprazan to lansoprazole (Fig. 2). Regarding the secondary endpoint, the proportions of patients without heartburn at 12 and 24 weeks in PPS analysis were not inferior in the tegoprazan group compared to the lansoprazole group. Additionally, symptom-free rates for acid regurgitation and epigastric pain or discomfort at 4, 12 and 24 weeks were not inferior in the tegoprazan group compared to lansoprazole group (Fig. 3). Using a superiority test to evaluate the statistical significance of the difference between the two groups, no statistically significant differences were observed in the proportion of subjects without NSAID-induced gastrointestinal symptoms for any item or time point, except for the proportion of subjects without heartburn at week 12 (tegoprazan 25 mg group 86.51% vs lansoprazole 15 mg group 76.69%, p=0.0421). Secondary endpoint. Proportion of patients without nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms at weeks 4, 12 and 24 (per-protocol set). (A) Heartburn. (B) Acid regurgitation. (C) Upper abdominal pain or discomfort. *Non-inferiority test (Wald method), p<0.025; †Chi-square test, p<0.05 In subgroup analyses, the incidence of peptic ulcers did not differ between the nonselective NSAID group and COX-2 selective inhibitor group, regardless of concomitant low-dose aspirin use or a history of gastroduodenal ulcer (Fig. 4). Subgroup analysis. Proportion of patients with gastric and/or duodenal ulcers at week 24. (A) History of gastroduodenal ulcer. (B) NSAID type. (C) Use of low-dose aspirin. PPS, per-protocol set; NSAID, nonsteroidal anti-inflammatory drug. 3. Safety The overall incidence of TEAEs was not significantly different between the tegoprazan group (28.8%, 55/191) and the lansoprazole group (34.36%, 67/195) (p=0.2399). Serious AEs were not significantly different between the tegoprazan group (1.57%, 3/191) and the lansoprazole group (2.56%, 5/195) (p=0.7238). Adverse drug reactions were also not significantly different between the tegoprazan group (13.09%, 25/191) and the lansoprazole group (16.41%, 32/195) (p=0.3578) (Table 3). Table 3Overall Summary of Subjects with TEAEsTegoprazan 25 mg (n=191)Lansoprazole 15 mg (n=195)SubjectNo. of eventsSubjectNo. of eventsTEAEsNo. (%)55 (28.80)9167 (34.36)10295% CI22.37–35.2227.69–41.02p-value0.2399*Serious TEAEsNo. (%)3 (1.57)35 (2.56) 595% CI0.33–4.520.84–5.88p-value0.7238†ADRsNo. (%)25 (13.09)3632 (16.41)4795% CI8.31–17.8711.21–21.61p-value0.3578*Serious ADRsNo. (%)1 (0.52)11 (0.51) 195% CI0.01–2.880.01–2.82p-value1.0000†TEAEs, treatment-emergent adverse events; CI, confidence interval; ADRs, adverse drug reactions.*Chi-square test; †Fisher exact test. Overall Summary of Subjects with TEAEs TEAEs, treatment-emergent adverse events; CI, confidence interval; ADRs, adverse drug reactions. *Chi-square test; †Fisher exact test. Clinical laboratory parameters remained stable from baseline to week 24 in both groups. Although changes in pulse rate and body temperature reached statistical difference in the lansoprazole group, there were no clinically relevant differences between the two groups overall (Table 4). Table 4Clinical Laboratory ResultsTegoprazan 25 mg (n=191)Lansoprazole 15 mg (n=195)BaselineEnd of study visitChangeBaselineEnd of study visitChangeHematologyWBC, ×103/mm3No.191181181195189189Mean±SD6.07±1.766.09±1.900.07±1.486.21±1.716.12±1.49–0.09±1.48Median5.845.800.045.966.00–0.10Range2.70 to 13.372.40 to 15.50–4.87 to 8.103.10 to 14.693.08 to 11.16–6.80 to 5.52p-value (within group)0.8645*0.7500*p-value (between group)0.7178†Hemoglobin, g/dLNo.191181181195189189Mean±SD13.66±1.2613.55±1.30–0.16±0.7013.73±1.3613.67±1.41–0.04±0.76Median13.6013.60–0.2013.6013.600.00Range7.90 to 16.909.10 to 16.70–1.70 to 2.1010.20 to 17.909.50 to 17.10–2.20 to 3.10p-value (within group)0.0006*0.1413*p-value (between group)0.1104†Blood chemistryTotal bilirubin, mg/dLNo.191181181195189189Mean±SD0.70±0.310.68±0.30–0.02±0.190.70±0.290.67±0.31–0.03±0.20Median0.650.61–0.030.650.610.00Range0.20 to 2.100.17 to 2.20–0.49 to 0.500.22 to 1.960.20 to 2.41–0.60 to 0.73p-value (within group)0.2378‡0.1155*p-value (between group)0.9519†AST (GOT), U/LNo.191181181195189189Mean±SD24.27±7.6825.13±9.090.78±7.3324.89±8.5524.74±9.80–0.05±8.83Median23.0023.001.0024.0023.00–1.00Range13.00 to 69.0012.00 to 97.00–28.00 to 28.0011.00 to 77.004.00 to 92.00–34.00 to 63.00p-value (within group)0.0732*0.2500*p-value (between group)0.0392†ALT (GPT), U/LNo.191181181195189189Mean±SD22.05±9.4722.86±14.900.75±13.4623.24±11.2023.45±14.660.50±11.95Median20.0020.000.0020.0020.00–1.00Range8.00 to 65.008.00 to 161.00–42.00 to 114.006.99 to 63.006.99 to 122.00–35.00 to 94.00p-value (within group)0.8426*0.3999*p-value (between group)0.4767†γ-GT, U/LNo.191181181195189189Mean±SD26.17±19.9228.88±39.832.36±29.8626.88±18.6024.63±15.42–1.44±11.21Median21.0020.000.0021.0020.00–1.00Range8.00 to 136.007.00 to 326.00–64.00 to 226.006.00 to 138.005.00 to 122.00–82.00 to 39.00p-value (within group)0.3246*0.0237*p-value (between group)0.2541†Magnesium, mmol/LNo.191181181195189189Mean±SD0.93±0.080.93±0.07–0.01±0.060.94±0.080.93±0.08–0.01±0.07Median0.920.920.000.960.940.00Range0.70 to 1.260.74 to 1.09–0.17 to 0.170.74 to 1.390.74 to 1.17–0.35 to 0.22p-value (within group)0.4716*0.2010*p-value (between group)0.4871†WBC, white blood cell; AST, aspartate aminotransferase; GOT, glutamic oxaloacetic transaminase; ALT, alanine aminotransferase; GPT, glutamic pyruvic transaminase; γ-GT, gamma-glutamyl transferase.*Wilcoxon’s signed rank test; †Wilcoxon’s rank sum test; ‡Paired t-test. Clinical Laboratory Results WBC, white blood cell; AST, aspartate aminotransferase; GOT, glutamic oxaloacetic transaminase; ALT, alanine aminotransferase; GPT, glutamic pyruvic transaminase; γ-GT, gamma-glutamyl transferase. *Wilcoxon’s signed rank test; †Wilcoxon’s rank sum test; ‡Paired t-test. DISCUSSION In this phase III, randomized, double-blind, active-controlled, multicenter trial, tegoprazan 25 mg demonstrated non-inferior efficacy to lansoprazole 15 mg in preventing NSAID-induced peptic ulcers over 24 weeks. The incidence of endoscopically confirmed ulcers was low in both groups in both PPS (1.49% vs 2.22%) and FAS (1.96% vs 1.84%) analyses, and the between-group differences were well within the prespecified non-inferiority margin of 8.3%. Symptom-based outcomes including heartburn, acid regurgitation, and epigastric discomfort were also comparable between groups. Tegoprazan was well tolerated, and the safety profile did not differ significantly from lansoprazole with respect to overall TEAEs, serious AEs, and adverse drug reactions. Although the absolute incidence of peptic ulcer was low in both groups, this likely reflects improvements in contemporary preventive strategies rather than a lack of therapeutic effect. In such a low-event setting, pharmacological predictability and consistency of acid suppression may represent clinically relevant differentiators, particularly for patients requiring long-term NSAID therapy. PPIs have been the established strategy to prevent NSAID-induced ulceration by suppressing gastric acid production.13 However, concerns regarding delayed onset, CYP2C19 metabolism dependency, and persistent nocturnal acid breakthrough remain. P-CABs such as tegoprazan offer rapid, potent, and sustained acid suppression, independent of CYP2C19 phenotype, with proven benefit in gastric ulcer healing and gastroesophageal reflux disease symptom control.14 Rather than suggesting superiority over PPIs, our findings support tegoprazan as a clinically viable alternative for patients in whom rapid onset, sustained acid suppression, or reduced metabolic variability are considered important. Previous trials have shown non-inferiority or superiority of P-CABs over PPIs in acid-related disorders.7-12 Our findings extend this evidence by demonstrating that tegoprazan is also effective in ulcer prevention in patients receiving long-term NSAID therapy. Notably, the efficacy was consistent across patients treated with non-selective NSAIDs and COX-2 inhibitors, with or without low-dose aspirin, and regardless of previous ulcer history. Despite advances in selective COX-2 inhibitors, many patients on chronic NSAID therapy—particularly older individuals and those with cardiovascular comorbidities—remain at substantial risk of peptic ulcers.15 The low ulcer incidence observed with tegoprazan suggests that it may serve as a practical alternative to PPIs in real-world settings. Furthermore, the predictable pharmacodynamics and minimal influence of CYP polymorphism on tegoprazan may provide benefits for populations who respond poorly to PPIs or who require consistent long-term acid suppression.16 This study has several limitations. First, although the 24-week duration is clinically relevant, it may not fully represent ulcer risk in patients requiring several years of continuous NSAID therapy. Long-term outcome studies would be valuable. Second, although H. pylori is a co-risk factor for peptic ulcer in NSAID users, infection status and history of eradication were not evaluated in this study, which is a limitation in the analysis of the results. Third, endoscopic assessment was conducted only at predefined visits, which may have missed asymptomatic intervals of superficial ulceration. However, newly developed ulcer scar in follow-up endoscopy was considered an interval ulcer during the study. Fourth, the exclusion of patients with severe comorbidities or active ulcer disease may limit generalizability to the highest-risk individuals. Finally, patient-reported gastrointestinal quality-of-life metrics were not extensively assessed, which could have provided further insight into therapeutic benefit. Nevertheless, these limitations are balanced by the rigorous randomized design, multicenter participation, and inclusion of both PPS and FAS analyses supporting robustness of the findings. Long-term studies on cost-effectiveness in routine NSAID management and combination use with antiplatelets are needed. In conclusion, tegoprazan 25 mg showed non-inferior preventive efficacy compared with lansoprazole 15 mg against NSAID-induced peptic ulcers over 24 weeks, with similarly favorable safety and symptom outcomes. These findings support tegoprazan as a promising gastroprotective agent for patients requiring long-term NSAID therapy. ACKNOWLEDGEMENTS This work was funded in full by HK inno.N, Icheon, Korea. The authors would like to thank all the investigators who contributed to this study. Statistical analysis was supported by Ga Young Goh, Haerim Jang, and Yu Gyeong Park, who are employees of HK inno.N Corp., Icheon, Korea. Footnotes CONFLICTS OF INTEREST Byung-Wook Kim is an editorial board member of the Gut and Liver but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported. AUTHOR CONTRIBUTIONS Study concept and design: J.J.K. Data acquisition: all authors. Data analysis and interpretation: S.G.K. Drafting of the manuscript: S.G.K. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: S.G.K. Obtained funding: J.J.K. Study supervision: J.J.K., S.K.L. Approval of final manuscript: all authors. DATA AVAILABILITY STATEMENT Data analyzed in this study are available from the corresponding author upon reasonable request. REFERENCES